Alejandra Méndez Romero, MD, PhD, on Liver Metastases: Dutch-Belgian Registry of Stereotactic Body Radiation
2019 ASTRO Annual Meeting
Alejandra Méndez Romero, MD, PhD, of Erasmus University Medical Center, discusses findings that show high local control rates with stereotactic body radiation for patients in this large published series, most of whom had colorectal cancer (Abstract 230).
Steven H. Lin, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses phase II findings that showed proton beam therapy improved total toxicity burden score with no difference in progression-free survival when compared with intensity-modulated radiation treatment (Abstract LBA2).
Youssef Zeidan, MD, PhD, of the American University of Beirut Medical Center, discusses study findings showing that, in patients with one to three positive lymph nodes, postmastectomy radiation treatment decreased the risk of locoregional recurrence, particularly in estrogen receptor–positive disease (Abstract 83).
Daniel M. Trifiletti, MD, of the Mayo Clinic, discusses study findings showing that, between two different radiation doses (30 Gy/10 fractions vs 37.5 Gy/15 fractions), there was no difference in the time to cognitive failure, tumor control, or overall survival for patients with brain metastases (Abstract 19).
Justin Barnes, MS, of the St. Louis University School of Medicine, discusses his findings on the risk of suicide, which is higher in patients with cancer than in other adults but can be reduced by health policy interventions, including components of the Affordable Care Act (Abstract LBA9).
Erica H. Bell, PhD, of The Ohio State University, discusses phase III findings from a prognostic and predictive molecular subgroup analysis of radiotherapy vs radiotherapy plus procarbazine/lomustine/vincristine in high-risk low-grade gliomas (Abstract 161).